CaMKII inhibitors: From research tools to therapeutic agents

Frontiers in Pharmacology

Volumn 5 FEB, Issue , 2014, Pages

  Pellicena, Patricia ^a   Schulman, Howard ^a  

^a Allosteros Therapeutics   (United States)

Author keywords

AC3 I; CaMKII; CaMKII inhibitors; CaMKIINtide; Cardiovascular disease; Kinase inhibitors; KN 62; KN 93

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; AUTOCAMTIDE 2 INHIBITOR PROTEIN; AUTOCAMTIDE 3 INHIBITOR; BOSUTINIB; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; HMN 709; IMATINIB; KN 92; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; PROTEIN CAMKIIN; PROTEIN CAMKIINTIDE; PROTEIN S 100; PROTEIN S100A1; PROTEIN SERCA2A; PROTEIN SERINE THREONINE KINASE INHIBITOR; RIMACALIB; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SCIOS15B; SUNITINIB; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; ENZYME STRUCTURE; GENE THERAPY; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS;

EID: 84895517603     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00021     Document Type: Review

References (85)

1. 2+/calmodulin-dependent protein kinase, decreases early after depolarizations in rabbit heart. J. Pharmacol. Exp. Ther. 287, 996-1006.
2. Anderson, M. E., Brown, J. H., and Bers, D. M. (2011). CaMKII in myocardial hypertrophy and heart failure. J. Mol. Cell Cardiol. 51, 468-473. doi: 10.1016/j.yjmcc.2011.01.012.
3. Anderson, M. E., Higgins, L. S., and Schulman, H. (2006). Disease mechanisms and emerging therapies: protein kinases and their inhibitors in myocardial disease. Nat. Clin. Pract. Cardiovasc. Med. 3, 437-445. doi: 10.1038/ncpcardio0585.
4. Asano, S., Komiya, M., Koike, N., Koga, E., Nakatani, S., and Isobe, Y. (2010). 5,6,7,8-Tetrahydropyrido[4,3-d]pyrimidines as novel class of potent and highly selective CaMKII inhibitors. Bioorg. Med. Chem. Lett. 20, 6696-6698. doi: 10.1016/j.bmcl.2010.09.005.
5. Backs, J., Backs, T., Neef, S., Kreusser, M. M., Lehmann, L. H., Patrick, D. M., et al. (2009). The δ isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc. Natl. Acad. Sci. U.S.A. 106, 2342-2347. doi: 10.1073/pnas.0813013106.
6. 2+ oscillations. EMBO J. 21, 3590-3597. doi: 10.1093/emboj/cdf360.
7. Bayer, K. U., Lebel, E., Mcdonald, G. L., O'Leary, H., Schulman, H., and De Koninck, P. (2006). Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B. J. Neurosci. 26, 1164-1174. doi: 10.1523/JNEUROSCI.3116-05.2006.
8. Bayer, K. U., and Schulman, H. (2001). Regulation of signal transduction by protein targeting: the case for CaMKII. Biochem. Biophys. Res. Commun. 289, 917-923. doi: 10.1006/bbrc.2001.6063.
9. Beauverger, P., Gegis, G., Biscarrat, S., Duclos, O., and McCort, G. (2012). 5-Oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases. US Patent, 0 277 220, 2012-11-01.
10. 2+-calmodulin-dependent protein kinase in human epithelial cells. J. Physiol. 488(Pt 1), 37-55.
11. Buard, I., Coultrap, S. J., Freund, R. K., Lee, Y. S., Dell'acqua, M. L., Silva, A. J., et al. (2010). CaMKII "autonomy" is required for initiating but not for maintaining neuronal long-term information storage. J. Neurosci. 30, 8214-8220. doi: 10.1523/JNEUROSCI.1469-10.2010.
12. Chang, B. H., Mukherji, S., and Soderling, T. R. (1998). Characterization of a calmodulin kinase II inhibitor protein in brain. Proc. Natl. Acad. Sci. U.S.A. 95, 10890-10895. doi: 10.1073/pnas.95.18.10890.
13. Chang, B. H., Mukherji, S., and Soderling, T. R. (2001). Calcium/calmodulin-dependent protein kinase II inhibitor protein: localization of isoforms in rat brain. Neuroscience 102, 767-777. doi: 10.1016/S0306-4522(00)00520-0.
14. Chao, L. H., Pellicena, P., Deindl, S., Barclay, L. A., Schulman, H., and Kuriyan, J. (2010). Intersubunit capture of regulatory segments is a component of cooperative CaMKII activation. Nat. Struct. Mol. Biol. 17, 264-272. doi: 10.1038/nsmb.1751.
15. 2+/calmodulin-dependent kinase II holoenzyme. Cell 146, 732-745. doi: 10.1016/j.cell.2011.07.038.
16. 2+ leak promotes atrial fibrillation in mice. J. Clin. Invest. 119, 1940-1951. doi: 10.1172/JCI37059.
17. Cohen, P., and Alessi, D. R. (2013). Kinase drug discovery-what's next in the field? ACS Chem. Biol. 8, 96-104. doi: 10.1021/cb300610s.
18. Colbran, R. J., Smith, M. K., Schworer, C. M., Fong, Y. L., and Soderling, T. R. (1989). Regulatory domain of calcium/calmodulin-dependent protein kinase II. Mechanism of inhibition and regulation by phosphorylation. J. Biol. Chem. 264, 4800-4804.
19. Colbran R. J. (2004). Targeting of calcium/calmodulin-dependent protein kinase II. Biochem. J. 378, 1-16. doi: 10.1042/BJ20031547.
20. Coultrap, S. J., and Bayer, K. U. (2011). Improving a natural CaMKII inhibitor by random and rational design. PLoS ONE 6:e25245. doi: 10.1371/journal.pone.0025245.
21. 2+/calmodulin-dependent protein kinase IV. Role in transcriptional regulation. J. Biol. Chem. 269, 15520-15527.
22. Erickson, J. R., Joiner, M. L., Guan, X., Kutschke, W., Yang, J., Oddis, C. V., et al. (2008). A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133, 462-474. doi: 10.1016/j.cell.2008.02.048.
23. Erickson, J. R., Patel, R., Ferguson, A., Bossuyt, J., and Bers, D. M. (2011). Fluorescence resonance energy transfer-based sensor Camui provides new insight into mechanisms of calcium/calmodulin-dependent protein kinase II activation in intact cardiomyocytes. Circ. Res. 109, 729-738. doi: 10.1161/CIRCRESAHA.111.247148.
24. Erickson, J. R., Pereira, L., Wang, L., Han, G., Ferguson, A., Dao, K., et al. (2013). Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature 502, 372-376. doi: 10.1038/nature12537.
25. Gao, Y., Davies, S. P., Augustin, M., Woodward, A., Patel, U. A., Kovelman, R., et al. (2013). A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J. 451, 313-328. doi: 10.1042/BJ20121418.
26. Gomez-Monterrey, I., Sala, M., Rusciano, M. R., Monaco, S., Maione, A. S., Iaccarino, G., et al. (2013). Characterization of a selective CaMKII peptide inhibitor. Eur. J. Med. Chem. 62, 425-434. doi: 10.1016/j.ejmech.2012.12.053.
27. Gutierrez, D. A., Fernandez-Tenorio, M., Ogrodnik, J., and Niggli, E. (2013). NO-dependent CaMKII activation during β-adrenergic stimulation of cardiac muscle. Cardiovasc. Res. 100, 392-401. doi: 10.1093/cvr/cvt201.
28. 2+/calmodulin-dependent protein kinase and mutational analysis of its autoregulation. Neuron 3, 59-70. doi: 10.1016/0896-6273(89)90115-3.
29. Hanson, P. I., Meyer, T., Stryer, L., and Schulman, H. (1994). Dual role of calmodulin in autophosphorylation of multifunctional CaM kinase may underlie decoding of calcium signals. Neuron 12, 943-956. doi: 10.1016/0896-6273(94)90306-9.
30. 2+/calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function. Annu. Rev. Biochem. 71, 473-510. doi: 10.1146/annurev.biochem.71.110601.135410.
31. Hund, T. J., Koval, O. M., Li, J., Wright, P. J., Qian, L., Snyder, J. S., et al. (2010). A β(IV)-spectrin/CaMKII signaling complex is essential for membrane excitability in mice. J. Clin. Invest. 120, 3508-3519. doi: 10.1172/JCI43621.
32. Huse, M., and Kuriyan, J. (2002). The conformational plasticity of protein kinases. Cell 109, 275-282. doi: 10.1016/S0092-8674(02)00741-9.
33. Ishida, A., Kameshita, I., Okuno, S., Kitani, T., and Fujisawa, H. (1995). A novel highly specific and potent inhibitor of calmodulin-dependent protein kinase II. Biochem. Biophys. Res. Commun. 212, 806-812. doi: 10.1006/bbrc.1995.2040.
34. 2+-calmodulin-dependent protein kinase II inhibitor on GABA release in cerebrospinal fluid of the rat. J. Pharmacol. Exp. Ther. 254, 598-602.
35. 2+/calmodulin-dependent protein kinase IIalpha/beta binding domain in densin that selectively modulates glutamate receptor subunit phosphorylation. J. Biol. Chem. 286, 24806-24818. doi: 10.1074/jbc.M110.216010.
36. Joiner, M. L., Koval, O. M., Li, J., He, B. J., Allamargot, C., Gao, Z., et al. (2012). CaMKII determines mitochondrial stress responses in heart. Nature 491, 269-273. doi: 10.1038/nature11444.
37. Khoo, M. S., Li, J., Singh, M. V., Yang, Y., Kannankeril, P., Wu, Y., et al. (2006). Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy. Circulation 114, 1352-1359. doi: 10.1161/CIRCULATIONAHA.106.644583.
38. Kolodziej, S. J., Hudmon, A., Waxham, M. N., and Stoops, J. K. (2000). Three-dimensional reconstructions of calcium/calmodulin-dependent (CaM) kinase IIα and truncated CaM kinase IIalpha reveal a unique organization for its structural core and functional domains. J. Biol. Chem. 275, 14354-14359. doi: 10.1074/jbc.275.19.14354.
39. Komiya, M., Asano, S., Koike, N., Koga, E., Igarashi, J., Nakatani, S., et al. (2012). Synthesis and structure based optimization of 2-(4-phenoxybenzoyl)-5-hydroxyindole as a novel CaMKII inhibitor. Bioorg. Med. Chem. 20, 6840-6847. doi: 10.1016/j.bmc.2012.09.048.
40. + channels in vascular myocytes. J. Pharmacol. Exp. Ther. 290, 1165-74.
41. Leonard, A. S., Lim, I. A., Hemsworth, D. E., Horne, M. C., and Hell, J. W. (1999). Calcium/calmodulin-dependent protein kinase II is associated with the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. U.S.A. 96, 3239-3244. doi: 10.1073/pnas.96.6.3239.
42. 2+ channels. Mol. Pharmacol. 42, 489-488.
43. Lu, Q., Chen, Z., Perumattam, J., Wang, D. X., Liang, W., Xu, Y. J., et al. (2008). Aryl-indolyl maleimides as inhibitors of CaMKIIδ. Part 3: importance of the indole orientation. Bioorg. Med. Chem. Lett. 18, 2399-2403. doi: 10.1016/j.bmcl.2008.02.057.
44. Luo, M., Guan, X., Luczak, E. D., Lang, D., Kutschke, W., Gao, Z., et al. (2013). Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J. Clin. Invest. 123, 1262-1274. doi: 10.1172/JCI65268.
45. 2+/calmodulin-dependent protein kinase II bound to the C-terminal domain of CaV2.1 calcium channels. J. Biol. Chem. 288, 4637-4648. doi: 10.1074/jbc.M112.369058.
46. Malinow, R., Schulman, H., and Tsien, R. W. (1989). Inhibition of postsynaptic PKC or CaMKII blocks induction but not expression of LTP. Science 245, 862-866. doi: 10.1126/science.2549638.
47. Mavunkel, B., Xu, Y. J., Goyal, B., Lim, D., Lu, Q., Chen, Z., et al. (2008). Pyrimidine-based inhibitors of CaMKIId. Bioorg. Med. Chem. Lett. 18, 2404-2408. doi: 10.1016/j.bmcl.2008.02.056.
48. 2+/calmodulin-dependent protein kinase V from rat cerebrum. J. Biol. Chem. 268, 9143-9147.
49. Morris, E. P., and Torok, K. (2001). Oligomeric structure of alpha-calmodulin-dependent protein kinase II. J. Mol. Biol. 308, 1-8. doi: 10.1006/jmbi.2001.4584.
50. Nagar, B., Bornmann, W. G., Pellicena, P., Schindler, T., Veach, D. R., Miller, W. T., et al. (2002). Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236-4243.
51. Patel, R., Holt, M., Philipova, R., Moss, S., Schulman, H., Hidaka, H., et al. (1999). Calcium/calmodulin-dependent phosphorylation and activation of human Cdc25-C at the G2/M phase transition in HeLa cells. J. Biol. Chem. 274, 7958-7968. doi: 10.1074/jbc.274.12.7958.
52. Payne, M. E., Fong, Y. L., Ono, T., Colbran, R. J., Kemp, B. E., Soderling, T. R., et al. (1988). Calcium/calmodulin-dependent protein kinase II. Characterization of distinct calmodulin binding and inhibitory domains. J. Biol. Chem. 263, 7190-7195.
53. Pleger, S. T., Brinks, H., Ritterhoff, J., Raake, P., Koch, W. J., Katus, H. A., et al. (2013). Heart failure gene therapy: the path to clinical practice. Circ. Res. 113, 792-809. doi: 10.1161/CIRCRESAHA.113.300269.
54. 2+/calmodulin-dependent protein kinase II triggers atrial fibrillation. Circulation 128, 1748-1757. doi: 10.1161/CIRCULATIONAHA.113.003313.
55. Rellos, P., Pike, A. C. W., Niesen, F. H., Salah, E., Lee, W. H., Von Delft, F., et al. (2010). Structure of the CaMKIIδ/calmodulin complex reveals the molecular mechanism of CaMKII kinase activation. PLoS Biol. 8:e1000426. doi: 10.1371/journal.pbio.1000426.
56. Rezazadeh, S., Claydon, T. W., and Fedida, D. (2006). KN-93 (2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinn amyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. J. Pharmacol. Exp. Ther. 317, 292-299. doi: 10.1124/jpet.105.097618.
57. 2+/calmodulin-dependent protein kinase II. J. Biol. Chem. 273, 28424-28429. doi: 10.1074/jbc.273.43.28424.
58. Rosenberg, O. S., Deindl, S., Sung, R. J., Nairn, A. C., and Kuriyan, J. (2005). Structure of the autoinhibited kinase domain of CaMKII and SAXS analysis of the holoenzyme. Cell 123, 849-860. doi: 10.1016/j.cell.2005.10.029.
59. Sag, C. M., Wadsack, D. P., Khabbazzadeh, S., Abesser, M., Grefe, C., Neumann, K., et al. (2009). Calcium/calmodulin-dependent protein kinase II contributes to cardiac arrhythmogenesis in heart failure. Circ. Heart Fail. 2, 664-675. doi: 10.1161/CIRCHEARTFAILURE.109.865279.
60. Sanders, P. N., Koval, O. M., Jaffer, O. A., Prasad, A. M., Businga, T. R., Scott, J. A., et al. (2013). CaMKII is essential for the proasthmatic effects of oxidation. Sci. Transl. Med. 5, 195ra197. doi: 10.1126/scitranslmed.3006135.
61. Sanhueza, M., Fernandez-Villalobos, G., Stein, I. S., Kasumova, G., Zhang, P., Bayer, K. U., et al. (2011). Role of the CaMKII/NMDA receptor complex in the maintenance of synaptic strength. J. Neurosci. 31, 9170-9178. doi: 10.1523/JNEUROSCI.1250-11.2011.
62. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., and Kuriyan, J. (2000). Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942. doi: 10.1126/science.289.5486.1938.
63. Scholten, A., Preisinger, C., Corradini, E., Bourgonje, V. J., Hennrich, M. L., Van Veen, T. A., et al. (2013). Phosphoproteomics study based on in vivo inhibition reveals sites of calmodulin-dependent protein kinase II regulation in the heart. J. Am. Heart Assoc. 2:e000318. doi: 10.1161/JAHA.113.000318.
64. Schulman, H. (2004). Activity-dependent regulation of calcium/calmodulin-dependent protein kinase II localization. J. Neurosci. 24, 8399-8403. doi: 10.1523/JNEUROSCI.3606-04.2004.
65. 2+/calmodulin-dependent kinase II triggers cell membrane injury by inducing complement factor B gene expression in the mouse heart. J. Clin. Invest. 119, 986-996. doi: 10.1172/JCI35814.
66. 2+/calmodulin-dependent protein kinase II antagonism. J. Biol. Chem. 277, 35061-35070. doi: 10.1074/jbc.M202928200.
67. Strack, S., Mcneill, R. B., and Colbran, R. J. (2000). Mechanism and regulation of calcium/calmodulin-dependent protein kinase II targeting to the NR2B subunit of the N-methyl-D-aspartate receptor. J. Biol. Chem. 275, 23798-23806. doi: 10.1074/jbc.M001471200.
68. 2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem. Biophys. Res. Commun. 181, 968-975. doi: 10.1016/0006-291X(91)92031-E.
69. Swaminathan, P. D., Purohit, A., Soni, S., Voigt, N., Singh, M. V., Glukhov, A. V., et al. (2011). Oxidized CaMKII causes cardiac sinus node dysfunction in mice. J. Clin. Invest. 121, 3277-3288. doi: 10.1172/JCI57833.
70. 2+/calmodulin-dependent protein kinases. Cell Mol. Life Sci. 65, 2637-2657. doi: 10.1007/s00018-008-8086-2.
71. Tagashira, S., and Fukushima, A. (2008). Combination drug for treating autoimmune disease. US Patent, 0 255 121, 2008-10-16.
72. Tao-Cheng, J. H., Yang, Y., Bayer, K. U., Reese, T. S., and Dosemeci, A. (2013). Effects of CaMKII inhibitor tatCN21 on activity-dependent redistribution of CaMKII in hippocampal neurons. Neuroscience 244, 188-196. doi: 10.1016/j.neuroscience.2013.03.063.
73. 2+/calmodulin-dependent protein kinase II. J. Biol. Chem. 265, 4315-4320.
74. 2+/CaM-dependent protein kinase genes. Gene 322, 17-31. doi: 10.1016/j.gene.2003.08.023.
75. 2+/CaM kinase). Cell Growth Differ. 6, 1063-1070.
76. Tsui, J., Inagaki, M., and Schulman, H. (2005). Calcium/calmodulin-dependent protein kinase II (CaMKII) localization acts in concert with substrate targeting to create spatial restriction for phosphorylation. J. Biol. Chem. 280, 9210-9216. doi: 10.1074/jbc.M407653200.
77. Vest, R. S., Davies, K. D., O'leary, H., Port, J. D., and Bayer, K. U. (2007). Dual mechanism of a natural CaMKII inhibitor. Mol. Biol. Cell 18, 5024-5033. doi: 10.1091/mbc.E07-02-0185.
78. Vest, R. S., O'leary, H., Coultrap, S. J., Kindy, M. S., and Bayer, K. U. (2010). Effective post-insult neuroprotection by a novel CaMKII inhibitor. J. Biol. Chem. 285, 20675-20682. doi: 10.1074/jbc.M109.088617.
79. Westra, J., Brouwer, E., Van Roosmalen, I. A. M., Doornbos-Van Der Meer, B., Van Leeuwen, M. A., Posthumus, M. D., et al. (2010). Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor. BMC Musculoskelet. Disord. 11:61. doi: 10.1186/1471-2474-11-61.
80. Woodgett, J. R., Davison, M. T., and Cohen, P. (1983). The calmodulin-dependent glycogen synthase kinase from rabbit skeletal muscle. Purification, subunit structure and substrate specificity. Eur. J. Biochem. 136, 481-487. doi: 10.1111/j.1432-1033.1983.tb07766.x.
81. Wu, Y., Gao, Z., Chen, B., Koval, O. M., Singh, M. V., Guan, X., et al. (2009). Calmodulin kinase II is required for fight or flight sinoatrial node physiology. Proc. Natl. Acad. Sci. U.S.A. 106, 5972-5977. doi: 10.1073/pnas.0806422106.
82. 2+/calmodulin-dependent protein kinase II (CaMKII) activity and sinoatrial nodal pacemaker cell energetics. PLoS ONE 8:e57079. doi: 10.1371/journal.pone.0057079.
83. Yokokura, H., Okada, Y., Terada, O., and Hidaka, H. (1996). HMN-709, a chlorobenzenesulfonamide derivative, is a new membrane-permeable calmodulin antagonist. Jpn. J. Pharmacol. 72, 127-135. doi: 10.1254/jjp.72.127.
84. Zhang, J., Li, N., Yu, J., Zhang, W., and Cao, X. (2001). Molecular cloning and characterization of a novel calcium/calmodulin-dependent protein kinase II inhibitor from human dendritic cells. Biochem. Biophys. Res. Commun. 285, 229-234. doi: 10.1006/bbrc.2001.5175.
85. Zhang, R., Khoo, M. S., Wu, Y., Yang, Y., Grueter, C. E., Ni, G., et al. (2005). Calmodulin kinase II inhibition protects against structural heart disease. Nat. Med. 11, 409-417. doi: 10.1038/nm1215.